A Phase 3, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (SONATA)

Shire1 site in 1 country332 target enrollmentOctober 16, 2012

ConditionsDry Eye Disease

InterventionsPlacebo Lifitegrast

DrugsLifitegrast Placebo

Overview

Phase: Phase 3
Intervention: Placebo
Conditions: Dry Eye Disease
Sponsor: Shire
Enrollment: 332
Locations: 1
Primary Endpoint: Number of Participants With Ocular and Nonocular Treatment Emergent Adverse Events (TEAEs) for 1 Year
Status: Completed
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of the study is to evaluate the safety of lifitegrast ophthalmic solution compared to placebo in the treatment of dry eye as assessed by ocular and non-ocular adverse events when administered BID for approximately 1 year.

Registry

clinicaltrials.gov

Start Date

October 16, 2012

End Date

March 3, 2014

Last Updated

4 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Shire

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Willing and able to read, sign and date the informed consent and HIPAA documents
•Willing and able to comply with all study procedures
•Be at least 18 years of age
•Patient-reported history of dry eye in both eyes
•A negative urine pregnancy test if female of childbearing potential and must use adequate birth control throughout the study period

Exclusion Criteria

•Any ocular condition that, in the opinion of the Investigator, could affect study parameters including, but not limited to, active ocular infection, ocular inflammation, glaucoma, and/or diabetic retinopathy
•Unwilling to avoid wearing contact lenses for 24h prior to Visit 1 and for some duration during the study
•Any blood donation or significant loss of blood within 56 days of Visit 1
•Any history of immunodeficiency disorder, positive HIV, hepatitis B, C, or evidence of acute active hepatitis A (anti-HAV IgM), or organ or bone marrow transplant.
•Use of any prohibited medications during the appropriate pre-study washout period and at any time during the study unless otherwise specified
•Any significant illness that could interfere with study parameters
•History of laser-assisted in situ keratomileusis (LASIK) or similar type of corneal refractive surgery within 12 months prior to Visit 1, and/or any other ocular surgical procedure within 12 months prior to Visit 1; or any scheduled ocular surgical procedure during the study period.
•Known history of alcohol and/or drug abuse
•Subjects with Dry eye secondary to scarring or destruction of conjunctival goblet cells (as with Vitamin A deficiency)